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Stem cells (SCs) represent a new therapeutic approach for spinal cord injury (SCI) by enabling improved sen-
sory and motor functions in animal models. The main goal of SC-based therapy for SCI is the replacement of 
neurons and glial cells that undergo cell death soon after injury. Stem cells are able to promote remyelination 
via oligodendroglia cell replacement to produce trophic factors enhancing neurite outgrowth, axonal elonga-
tion, and fiber density and to activate resident or transplanted progenitor cells across the lesion cavity. While 
several SC transplantation strategies have shown promising yet partial efficacy, mechanistic proof is gener-
ally lacking and is arguably the largest impediment toward faster progress and clinical application. The main 
challenge ahead is to spur on cooperation between clinicians, researchers, and patients in order to define and 
optimize the mechanisms of SC function and to establish the ideal source/s of SCs that produce efficient and 
also safe therapeutic approaches.
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INTRODUCTION
Spinal cord injury (SCI) is a devastating disorder 
with frustrating implications both for the individual and 
the society. Spinal cord injury has a profound effect on 
a patient’s physical and psychosocial well-being because 
it often results in permanent loss of bodily functions 
affecting limb movement, somatosensation, reproductive 
organs, bladder, and bowel. With respect to the costs of 
health care and living expenses, SCI poses a substantial 
burden on the healthcare system: the average lifetime cost 
of treating an individual with SCI is up to $2 million with 
$7 billion spent annually for caring for the SCI patients in 
the US alone (70).
By definition, SCI can be traumatic and nontraumatic, 
depending on the cause of injury (Table 1). Epidemiological 
data show that the incidence of traumatic SCI in the US 
ranges from 27 to 83 per million while in Europe it is 
approximately 10–30 new cases per million (41,117). The 
prevalence of nontraumatic spinal cord lesions is unknown 
due to the absence of state and federal registries. Spinal 
cord injury results in the marked loss of neurons and other 
cell types at injury site immediately after injury which is 
exacerbated with time. The pathophysiology of SCI can 
be divided clinically into two phases: primary injury phase 
and secondary injury phase (Fig. 1 and Table 2).
Primary Injury Phase
Primary injury is due to the direct compression and 
contusion of the spinal cord by fractured and displaced 
bone fragments and disc material as a result of fracture–
dislocation or burst fracture of the spine (92). The nerve 
cells are damaged, axons are disrupted, and neural cell 
membranes are ruptured. Injury of blood vessels is fol-
lowed by microhemorrhages in the central gray matter 
1310 VOLAREVIC ET AL.
that spreads out radially and axially, leading to spinal cord 
swelling and secondary ischemia (70). Ischemia, altered 
ion balance, and toxins (24) released from disrupted neu-
ral membranes trigger a secondary injury cascade that 
further exacerbates SCI.
Secondary Injury Phase
The secondary injury phase is described as a complex 
damage that occurs at the cellular level as a result of an 
interrelated series of pathophysiological processes includ-
ing electrolyte imbalance, ischemia, excitotoxicity, oxi-
dative stress, inflammation, and massive cell death due 
to immune response to the injury (92). Secondary injury 
starts with depolarization and voltage-dependent opening 
of sodium, potassium, and calcium ion channels. Overload 
of calcium ions initiates mitochondrial dysfunction and 
the activation of cytoplasmic nitric oxide synthase and 
phospholipase A2, which leads to microvascular damage 
and consequential ischemia (35). Damaged cells, axons, 
Table 1. The Main Causes of Spinal Cord Lesions
The main causes of traumatic SCI are:
 1. motor vehicle accidents
 2. violence
 3. falls
 4. recreational activities
The main causes of nontraumatic SCI are:
 1. genetic and metabolic diseases of CNS
 2. degenerative disorders of CNS
 3.  primary and metastatic (intramedullary and extramedul-
lary) tumors
 4. congenital and developmental diseases of CNS
 5.  infectious (viral, bacterial, fungal, parasitic) and inflam-
matory diseases
 6. toxins
 7. ischemic diseases of CNS
CNS, central nervous system.
Figure 1. The mechanisms involved in spinal cord injury. Spinal cord injury can be sustained through different mechanisms, with the 
following common main abnormalities leading to tissue damage: (i) destruction from direct trauma; (ii) compression by bone frag-
ments, hematoma, or disk material; and (iii) ischemia from damage or impingement of the spinal blood vessels.
STEM CELLS AND SPINAL CORD INJURY 1311
and blood vessels release toxic chemicals including glu-
tamate that attack intact neighboring cells in a highly dis-
ruptive process known as excitotoxicity (70). Glutamate, 
normally secreted in minimal amounts at the end tips of 
many axons, binds to receptors on target neurons and 
stimulates them to conduct impulses. After SCI, gluta-
mate is massively released from injured spinal neurons, 
axons, and astrocytes, overexciting neighboring neurons 
and triggering the production of free radicals. During the 
progression of SCI, the level of free radicals constantly 
increases at the lesion site leading to the reduction in 
membrane permeability. Cascades of radical-mediated 
peroxidation affect cell membranes through oxidation of 
lipid bilayer membranes and disrupt the electron trans-
port chain portion of the metabolic process (31). The 
loss of ionic homeostasis accompanied by excitotoxicity 
and oxidative stress leads to massive cell death in SCI. 
Many functional neurons and glia including oligoden-
drocytes (the nervous system’s myelin-producing cells) 
die by apoptosis and necrosis (7). Although the precise 
mechanism of oligodendrocyte apoptosis is not clearly 
known, oligodendrocytes can undergo excitotoxic cell 
death through their glutamate receptors or through Fas 
receptor/Fas ligand interaction (5,12). This is achieved 
by activation of Fas receptors (located on the surface of 
oligodendrocytes) and by Fas ligands that are expressed 
by activated microglia (12) triggering caspase-mediated 
apoptotic cell death of oligodendrocytes. The loss of 
oligodendrocytes effectively initiates axon demyelination 
and blocks transmission of action potentials.
The blood–brain barrier normally works as a highly 
selective filter that prevents influx of mononuclear cells 
(MNCs) from the blood into the central nervous system 
(CNS). However, SCI results in increased permeability of 
the blood–brain barrier, allowing massive MNC infiltra-
tion in the medullar tissue that triggers an inflammatory 
response. At the injury site, levels of proinflammatory 
cytokines, particularly interleukin 1a and -b, and tumor 
necrosis factor-a (86) are increased, leading to the activa-
tion of microglia cells (51). In turn, activated microglia 
cells increase the expression of monocyte chemoattractant 
protein-1 and chemokines that direct leukocytes to the 
site of injury (2), promoting inflammation. Furthermore, 
as previously described, activated microglia cells express 
Fas ligands that interact with Fas receptors on neurons and 
oligodendrocytes, initiating apoptotic cell death. In SCI 
cases, microglia cells activate T-cells that pass through 
the blood–brain barrier and infiltrate damaged spinal cord. 
Both T lymphocytes and glial cells are able to protect neu-
rons from secondary degeneration either by releasing neu-
rotrophins (T-cells) or by forming scars (glial cells) that 
isolate neural tissue from inflammatory cells and decrease 
neuroinflammation (33,73). Several hours after SCI, astro-
cytes in the lesion site proliferate, join together tightly, and 
form astrocytic (glial) scars that are beneficial for the rees-
tablishment of physical and chemical integrity of the spinal 
cord but are also responsible for prevention and complica-
tions of neuroregeneration (33).
The commonly affected areas of SCI are the cervical 
and lumbar spine. Damage to upper motoneurons results in 
hyperreflexia, hypertonia, and muscle weaknesses, while 
the insults to lower motoneurons cause hypo reflexia, hypo-
tonia, and muscle atrophy (69,114). After SCI, the entire 
nervous system should be carefully examined because 
posttraumatic multilevel cord injury is not rare and SCI 
could be accompanied by serious brain injury (19). The 
severity of SCI is determined by neurological assessment 
often using the five-level (A–E) American Spinal Injury 
Association (ASIA) impairment scale (70). Although vari-
ous bodily functions are affected after SCI, the absence of 
bowel and bladder control, limitations in hand use, and dif-
ficulty in breathing are critical (70); therefore, the primary 
goal of restorative therapy for SCI should be improvement 
of these functions. This could be achieved by preventing 
progressive cell death through replacement of damaged 
cells, by repairing the myelin sheath, and by reconnecting 
injured nerve fibers with their original targets that all lead 
to partial or complete rehabilitation of nerve and muscle 
function. Preclinical and clinical studies have shown that 
SCs might play an important role in many of these pro-
cesses. Therefore, we review here the potential of human 
Table 2. A Summary of Pathophysiological Events Following 
SCI
Primary injury phase
 1.  Direct compression and contusion of the spinal cord by 
fractured and displaced bone fragments and disc materials
 2. Neural cell injury and disruption of axons
 3.  Alteration of ion balance and toxin release from disrupted 
neural membranes
 4.  Microhemorrhagia and secondary ischemia due to blood 
vessel injury
Secondary injury phase
 1.  Excitotoxicity due to glutamate release from damaged 
cells, axons, and blood vessels
 2.  Electrolyte imbalance, increased production of free radi-
cals and oxidative stress
 3.  Inflammation due to the loss of blood–brain barrier and 
leukocyte migration to the injury site
 4.  Immune response including secretion of proinflammatory 
cytokines, microglia activation, astrocyte proliferation 
and glial scar formation
 5. Fas receptor activation and caspase cascade initiation
 6. Apoptosis and necrosis of neural cells
 7. Axonal damages and demyelination
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embryonic SCs (hESCs), adult SCs (ASCs) including mesen-
chymal SCs (MSCs), neural SCs (NSCs), and a new source 
of reprogrammed somatic cells: induced pluripotent SCs 
(iPSCs) as a potential therapeutic agent in the treatment of 
SCI (Table 3).
CURRENT STEM CELL-BASED THERAPIES 
FOR SPINAL CORD INJURY
Human Embryonic Stem Cells
Human embryonic stem cells are pluripotent cells de -
rived from the inner cell mass of the early blastocyst 
with the ability to proliferate for a long period under in 
vitro conditions and with a potential for differentiation 
into a broad range of cell types including specific cells of 
neuronal or glial fates (26). In view of this, hESCs are a 
promising source for generation of differentiated oligo-
dendrocytes and motoneurons (63,78), as a potential novel 
approach to treat SCI. Clinical applications of hESCs 
critically depend on their ability to differentiate toward 
defined and purified neural cell types in vitro. Recently, 
considerable progress has been achieved. Several stud-
ies, including our own (4,25,26,32,63,78), have focused 
on the improvement of the methods for predifferentia-
tion of hESCs into neural or neuronal precursors prior to 
cell transplantation in animal models of SCI. As a result 
improved protocols for relatively efficient generation and 
propagation of motoneuron progenitors (MPs) and oligo-
dendrocyte progenitors (OPCs) via targeted differentia-
tion of hESCs have been developed (25,78). Motoneuron 
progenitors derived from hESCs have the ability to mature 
and develop fundamental functions of normal motoneu-
rons in vitro including directional growth of long axons 
(25). Transplantation of hESC-derived OPCs can effi-
ciently recover locomotor function in contusion and 
transection animal models of SCI (25,78). Furthermore, 
in contusion models of SCI, surviving axons persist in 
the subpial rim of white matter. Most importantly, trans-
planted hESC-derived OPCs survive, integrate, differ-
entiate, and remyelinate damaged tissue, resulting in a 
significant improvement of locomotor function of rats 
with spinal cord contusions (78).
For a long time, it was believed that, after complete 
spinal transaction, there were no spared host axons or 
spontaneous regeneration (41,70). However, we recently 
demonstrated (25) that OPCs and MPs derived from 
hESCs, when transplanted into the rat spinal cord imme-
diately after injury, have the ability to migrate and engraft 
for at least 4 months. The main mechanism responsible 
for locomotor recovery of these animals is the ability of 
hESC-derived OPCs and MPs to differentiate into neu-
ronal and glial cells after transplantation. However, it 
seems that the regenerative mechanism of hESC therapy 
for SCI does not depend exclusively on the differentia-
tion potential of transplanted cells. Immunomodulatory 
characteristics of transplanted hESC-derived OPCs could 
also be responsible for the significant recovery of ani-
mals after SCI. Within the lesion, SCs and hESC-derived 
OPCs are able to generate a paracrine/trophic environ-
ment and modulate the local immune response promoting 
neuronal protection and activation of endogenous neuro-
genesis (50,74,87).
Despite promising results obtained in preclinical stud-
ies, there are several concerns regarding the safety of 
transplantation of hESCs in humans, including the for-
mation of teratoma (64). The possible reason for this 
problem could be the usage of different cell lines, various 
differentiation protocols, and transplantation of hetero-
geneous cell populations. Therefore, prolonged differ-
entiation of hESCs (8), inhibition of signaling pathways 
activating cell proliferation (13,64), and pure cell popu-
lation eliminates the incidence of tumor formation (8). 
As a consequence, a range of clinical trials involving 
administration of hESCs or hESC-derived OPCs for SCI 
treatment has already taken place including the one from 
Geron, which attempted to discern the safety of stem cell 
therapy in SCI on humans by using hESC-derived OPCs 
(known as “GRNOPC1”) in order to remyelinate axons 
within the injured spinal cord (for more information, 
Table 3. Therapeutic Potential of Stem Cells for Treatment of 
Spinal Cord Injury
Stem cells that have the ability to differentiate toward defined  
 neural cell types in vitro:
 hESCs and iPSCs: neurons, glial cells and motoneurons.
  MSCs: NSCs, neurons, astrocytes, oligodendrocytes and  
 Schwann cells.
 NSCs: neurons, oligodendrocytes and astrocytes.
Main mechanisms responsible for functional recovery of  
 stem cell-treated animal models of spinal cord injury:
  hESCs: differentiation into neuronal and glial cells, modu- 
 lation of local immune response, neuronal protection and  
 activation of endogenous neurogenesis.
  MSCs: providing trophic support to damaged neurons by  
 secreting angiogenic and neurotrophic factors and modula- 
 tion of local immune response.
 NSCs: differentiation into oligodendrocytes and astrocytes.
Limitations for stem cell-based therapy in humans:
 hESCs and iPSCs: potential for tumor formation.
  MSCs: the proof of functional neurons derived from trans- 
 planted MSCs has not been provided yet.
  NSCs: graft rejection, lack of neurotrophic factors, decrease  
  of differentiation potential after several passages, forma-
tion of glial scars.
  hESCs, human embryonic stem cells; MSCs, mesenchymal  
 stem cells; NSCs, neural stem cells; iPSCs, induced pluri- 
 potent stem cells.
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please see http://www.geron.com/GRNOPC1Trial). Food 
and Drug Administration (FDA) regulatory authority 
halted the Geron trial after preclinical studies showed that 
some of SCI animals treated with Geron’s cell line devel-
oped small spinal cysts at the treatment site. The FDA 
requested further characterization of differentiated cells 
and more preclinical trials with GRNOPC1 cells in ani-
mal models. The company subsequently reported to have 
identified batches of GRNOPC1 cells that did not cause 
cyst formation in animal models. Following these results, 
the company received regulatory approval to proceed 
with clinical trials, and the first patient with SCI received 
GRNOPC1 cells in October 2010. All patients enrolled 
in the Geron trial received GRNOPC1 cells within acute 
phase (7–14 days after SCI). This strategy was based on 
the studies conducted in animal models that showed that 
transplantation of cells in chronic phase results in insig-
nificant remyelination and poor locomotor improvement 
(50). Patients with thoracic SCI are more often enrolled in 
Phase 1 clinical trials for cell transplantation than people 
with other SCI types since the cell loss in these patients 
may not be life threatening as opposed to cervical injury. 
Regarding this matter, all patients enrolled in the Geron 
trial had a thoracic ASIA grade A SCI with neurological 
levels of T3 to T10. Unfortunately, in November 2011, 
due to financial reasons, the company announced the end 
of the medical research using hESCs for treatment of SCI 
and stated that the data obtained from enrolled Phase 1 
patients will be available in 2013.
Adult Stem Cells
Adult SCs (ASCs) have been identified in many organs 
and tissues including bone marrow, brain, spinal cord, 
skin, skeletal muscle, and bone (88). Depending on the 
tissue of origin, ASCs exhibit the potency to differentiate 
into multiple or specific cell types, and their main role is 
believed to be protective (88).
Although numerous preclinical studies have been con-
ducted, there is still no unique consensus about which 
types of ASCs are most effective for the treatment of SCI. 
Transplantation of MSCs, olfactory ensheathing cells 
(OECs), and NSCs showed similar effects in the experi-
mental models of SCI (38,67). All these cells are able to 
incorporate into damaged spinal cord and promote regen-
eration of damaged axons, leading to partial neurological 
improvements (38).
Significantly higher bar grip power and spontaneous 
motor activity were noticed in marmosets with contused 
spinal cords after transplantation of in vitro-expanded 
human NSCs (43), while enhanced regenerative sprouting 
of the rubrospinal tract, better locomotion, and hind limb 
function were seen in rats with SCI after implantation of 
OECs overexpressing the trophic factor neurotrophin-3 
(94). Although the precise mechanisms by which SCs 
function in SCI are still unknown, it seems that different 
SCs showed similar beneficial effect by using different 
mechanisms: NSCs mainly differentiate into neurons, 
astrocytes, and oligodendrocytes in spinal cord lesions, 
while MSCs principally act as neuroprotectors by secret-
ing various angiogenic and neurotrophic factors provid-
ing trophic support to damage neurons (Fig. 2) (53,95).
Mesenchymal Stem Cells
Due to their immunomodulatory ability and capac-
ity for self-renewal and differentiation into tissues of 
mesodermal origin, MSCs are ASCs that are most often 
used in preclinical and clinical studies for the treatment 
of various diseases including SCI. Although many stud-
ies (82,88,96,119) optimistically reported that MSCs 
could be transdifferentiated or converted into NSCs, neu-
rons, astrocytes, oligodendrocytes, and Schwann cells 
(37,49,113), definitive proof of functional neurons derived 
from transplanted MSCs has not been provided. There is 
a general agreement in the literature that the benefits of 
MSC therapy in SCI are a result of indirect environmental 
modification rather than direct translineage conversion 
to functional oligodendrocytes or neurons (93). In SCI 
treatment, MSCs are thought to act as neuroprotectors 
by secreting various angiogenic and neurotrophic factors 
such as brain-derived neurotrophic factor, nerve growth 
factor, vascular endothelial growth factor, and hepatocyte 
growth factor (53,95), providing trophic support to dam-
aged neurons and resulting in clinical improvement in 
patients with SCI.
The most widely applied SC-based therapy for SCI 
treatment in humans is the transplantation of bone mar-
row (BM)-derived MSCs (BMMSCs) (93). Mesenchymal 
SCs can be safely and easily obtained from human BM, 
and autologous transplantation of BMMSCs is a mini-
mally invasive procedure that could be used successfully 
as novel cell-based transplant strategy for SCI therapy 
(93). During the last 5 years, several clinical trials, using 
transplantation of autologous BMMSCs for treatment of 
patients with SCI, were performed in Brazil (10,17), India 
(57,80), Argentina (75), Czech Republic (100), Russia 
(14), Turkey (21), and South Korea (118). Autologous 
BMMSCs were transplanted around the spinal cord lesion 
in 35 patients with complete SCI (patients were in acute, 
subacute, and chronic stages of the disease) (118). The 
main side effect was neuropathic pain observed in 7.7% of 
MSC-treated patients (118). During the 10-month follow- 
up period, 30.4% of patients who received MSCs in acute 
and subacute stages showed significant improvements in 
the ASIA scale (118). Sykova et al. (100) suggested that 
MSCs should be transplanted during a so-called thera-
peutic window of 3–4 weeks following SCI, which is, 
according to their results, critical for the success of MSC-
based therapy for SCI (100). Intravenous or intraarterial 
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injection of autologous BMMSCs resulted in sensory 
and motor improvements in five of eight patients with 
complete SCI in the subacute stage of disease, while sig-
nificant recovery of locomotor functions was observed 
in only 1 of 12 chronic patients with SCI (100). Another 
large clinical trial performed in India (57), consisting of 
297 patients with chronic SCI, showed that intrathecal 
transplantation of autologous BMMSCs leads to clinical 
improvements in patients with chronic SCI. However, 
caution should be exerted when results from this study are 
interpreted. Patients are followed up for only 3 months, 
and detailed information about the period from injury 
to MSC transplantation was not obtained (57). Other 
studies have also shown improvements in MSC-treated 
patients that are in the chronic stage of SCI (10,17,21). 
Neurological improvements were seen in 66.7% (14) and 
100% (10), respectively, of patients with chronic SCI 
enrolled in clinical trials performed in Russia and Brazil. 
In these studies, cells were transplanted either directly 
in the lesion or intravenously and intrathecally simul-
taneously. In addition, after a 30-month follow-up trial, 
Cristante and coworkers (17) showed that intraarterial 
Figure 2. The main mechanisms responsible for functional recovery of stem cell-treated animal models with spinal cord injury (SCI). 
Transplantation of NSCs, OPCs, and OECs efficiently recovered locomotor function in both contusion and transection animal models 
of SCI, while MSCs act as neuroprotectors and promote early functional recovery after SCI by secreting various angiogenic and neuro- 
trophic factors. MSC, mesenchymal stem cell; NSC, neural stem cell; OEC, olfactory ensheathing cell; OPC, oligodendrocyte progenitor.
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delivery of BMMSCs resulted in electrophysiological 
improvement in chronic SCI patients with paraplegia or 
tetraplegia.
Although results from these clinical studies are prom-
ising, all these trials showed no universal consistency in 
terms of donor age/sex and cell passaging/culture condi-
tions. As the mechanism by which MSCs function remains 
unknown and considering the inconsistency associated 
with cell sourcing and conditions employed, further stud-
ies must be done in order to isolate and characterize more 
homogeneous BMMSC populations to obtain reliable, 
repeatable results.
Olfactory Ensheathing Cells
OECs are specialized glial cells that are found in the 
nerve fiber layer of the olfactory bulb and in the nasal 
olfactory mucosa (102). Based on their unique property 
of bridging the peripheral and CNS and providing a chan-
nel for peripheral axonal growth into the CNS (89), sev-
eral preclinical studies investigated therapeutic potential 
of OECs in the treatment of incomplete and complete 
SCI and reported neural tissue sparing, axon remyelina-
tion, and significant improvements in motor performance 
after OEC transplantation (28,30,42,56,66,76,90,91). The 
improvements depended on the SCI model, the duration 
of the study, the source, the age, and the methods used to 
prepare and transplant the OECs (29). Cells derived from 
the olfactory bulbs of adult rodents were the most com-
monly used in the SCI studies (105). The most promis-
ing OECs for SCI therapy were p75-nerve growth factor 
receptor (NGFR)-positive OECs (94). These cells were 
able to promote axon regeneration, intermingle with 
astrocytes, and migrate well within the reactive astro-
cytic environment after injury (58,59). Severe contusions 
of the spinal cord in a rat model were efficiently treated 
after cotransplantation of BMSCs and human p75-positive 
OECs harvested from the outer layers of the olfactory 
bulbs from human fetuses (22). Although there was no 
functional improvement of thoracic SCI after injection 
of OECs alone, the transplantation of both OECs and 
Schwann cells promoted behavioral benefits in contused 
animals (84). In the experimental models of complete tho-
racic transaction, transplantation of OECs resulted in the 
regeneration of corticospinal axons and led to improve-
ments of motor behavior 3 and 7 months after injury 
(56,90). In addition, studies that investigated therapeutic 
potential of adult bulb-derived OECs transplanted in ani-
mals with partial spinal cord lesion showed that OECs 
were able to improve directed forepaw reaching after 
dorsal column transection, as well as electrolytic lesions 
of the dorsal columns (65,77). These improvements are 
likely to be due to corticospinal axon regeneration and/or 
the enhancement of plasticity and neural cell sparing in 
the host spinal cord.
In rats with spinal cord unilateral cervical (C4) corti-
cospinal transaction, functional improvements and behav-
ioral benefits were noticed after transplantation of adult 
bulb-derived OECs that were genetically engineered to 
express the trophic factor neurotrophin-3 (94). These OECs 
were far more effective in promoting long-distance main-
tenance/regeneration of lesioned corticospinal axons 
due to the enhanced plasticity and neuroprotection (94). 
Data from experimental studies suggest that facilitation 
of axonal regrowth, remyelination, and neuroprotection 
are the main mechanisms responsible for the therapeu-
tic effects of OECs (89,102,105). However, data from 
clinical studies that used OECs for the treatment of SCI 
patients were not encouraging (89). Feron and colleagues 
(27) reported neither adverse effects nor neurological 
improvement in patients with complete thoracic SCI 
1 year after transplantation of autologous OECs. Lima and 
colleagues (68) transplanted minced olfactory mucosa 
tissue in the cavity of the cervical and thoracic SCI. 
According to their results, olfactory mucosa autograft 
transplantation into the human injured spinal cord is fea-
sible and relatively safe. However, the treatment was not 
significantly efficient. The problem is that they used tis-
sue that contains OECs but also many other cell types.
Taken together, these data suggest that there is obvi-
ously a significant difference between promising results 
obtained from preclinical studies versus discouraging 
data from clinical trials. The reason for this discrepancy 
is not fully understood, but variability of the cell sources 
and culture conditions could be important contributing 
factors (105), suggesting that protocols for OEC isolation 
and growth need improvement.
Adult and Fetal-Derived Neural Stem Cells
Adult neural SCs are a subpopulation of ASCs naturally 
present in the adult brain and spinal cord. In the brain, mul-
tipotent NSCs reside in the periventricular subependymal 
layer and the subgranular zone of the dentate gyrus, while in 
the spinal cord, they can be found in the ependymal regions 
lining the central canal (36,71,74,106,116). Astrocyte and 
oligodendrocyte progenitors reside throughout the neural 
axis compiling 3–5% of all glial cells (106,116). A remark-
able and underappreciated mechanism of self-repair is the 
proliferation of NSCs and glial progenitor cells following 
SCI. This robust response leads to significant replacement 
of glial elements and correlates to the period of early func-
tional recovery seen in incomplete lesions (116). Newly 
generated progenitors, including multipotent ependymal 
and glial progenitor cells, home to the lesion site where 
they differentiate into both astrocytic-like and oligoden-
droglial lineage cells, indicating their regenerative poten-
tial (36,71,74,120). Early after injury, some progenitor 
populations participate in scar formation as noted in SCI 
and demyelinating lesions (106). However, the majority 
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of the replaced glia are oligodendrocytes, and recent data 
demonstrate that these cells afford significant myelin res-
toration of spared axons (61).
Although NSCs have the potential to differentiate into 
neurons, oligodendrocytes, and astrocytes in vitro (40), 
it is believed that, following SCI, endogenous NSCs dif-
ferentiate mostly into oligodendrocytes and astrocytes (6). 
Despite significant endogenous cellular replacement that is 
mediated by NSCs, injury repair is incomplete. Of particu-
lar note is the lack of repair at the lesion epicenter, which 
remains the domain of the immune system (1). Despite a 
significant homing effect of NSCs to the lesion epicenter, 
there are clearly factors (such as netrin) that prevent pro-
genitor cells from regenerating the lesion core as occurs in 
regenerative species such as urodeles and fish (85). Indeed, 
understanding how to boost endogenous cellular replace-
ment, particularly in the lesion core, is an underdeveloped 
research area that has big clinical potential.
Many investigators have achieved successful but par-
tial functional improvement by supplementation of en -
dogenous NSC activity with transplanted NSCs. Our 
group has recently reported a functional motor recovery 
after transplantation of OPCs differentiated from ependy-
mal stem progenitor cells that were derived from the 
adult rat spinal cord suffering a traumatic lesion (74). 
Oligodendrocytes are able to remyelinate the axons in 
white matter, and astrocytes may secrete many neuro-
trophic factors supporting axonal regeneration and cell 
survival (16,20,52). Although several studies confirmed 
that transplantation of adult spinal cord-derived NSCs pro-
motes early functional recovery after SCI (43,83), there 
are very few reports (8,39,48) that describe the precise 
mechanism of action and factors responsible for integra-
tion of transplanted NSCs in injured spinal cord. It seems 
that the source of transplanted NSCs and methods used 
for their isolation prior to implantation are critical for a 
successful NSC survival and integration after transplanta-
tion in damaged spinal cord (39,48). Additionally, time of 
transplantation, the method of immunosuppression used, 
and type of injury (contusion vs. transection) affect the 
mechanism(s) of recovery (26,93). Several shortcomings 
limit their clinical use including formation of glial scars 
and the lack of neurotrophic factors after NSC trans-
plantation. Since most sources of NSCs are exogenous 
allograft or xenograft, their transplantation may cause 
graft rejection (41). In addition, the differentiation poten-
tial of NSCs decreases after several passages under in 
vitro conditions (3,115). Despite these challenges, a part 
of the scientific community believes that NSCs represent 
an ideal candidate for cell-based treatment of SCI due to 
functional improvement noticed after their transplanta-
tion (18,39,48,74), low rates of tumorigenesis (52), and 
the opportunity for autologous transplantation (41).
In addition to adult-derived NSCs, neural and glial 
precursors derived from postnatal and fetal nervous sys-
tem also show therapeutic promise. Investigators have 
used neural and glial-restricted precursors that produce 
functional improvement when injected early after injury 
(11). Multipotent populations of NSCs have been gener-
ated from human fetal tissue transplanted into immune-
compromised mice (39). Unlike adult NSCs, fetal-derived 
NSCs generate neurons in addition to glia in the injured 
spinal cord. The almost singular proof that human fetal 
NSCs transplanted at subchronic periods generate func-
tional improvements in mice has generated enough excite-
ment to proceed to a clinical trial. Swissmedic, the Swiss 
regulatory agency for therapeutic products, has autho-
rized a Phase I/II clinical trial in which SCI patients will 
receive human purified NSCs at 3 and 12 months postin-
jury. This NSC-based therapy for SCI is being developed 
by Anderson and Cummings of UC Irvine’s Sue and Bill 
Gross Stem Cell Research Center in collaboration with 
researchers at StemCells, Inc., and is expected to begin 
in 2011 at the Zurich’s University Hospital, Balgrist (for 
more information, please see http://www.today.uci.edu/
news/2010/12/nr_swisstrial_101207.php).
Looking to the Future: Induced Pluripotent Stem Cells
A scientific breakthrough achieved by Takahashi and 
Yamanaka in 2006 (101) demonstrated that it is possi-
ble to reprogram somatic cells back to the pluripotency 
stage by transducing a few key transcription factors cre-
ating iPSCs. Upregulation of “Yamanaka factors”: sex-
determining region Y box-containing gene 2 (SOX2), 
octamer-binding transcription factor 3/4 (OCT4), tumor 
suppressor Krüppel-like factor 4 (KLF4), and protoonco-
gene c-MYC allow somatic cells from mice and humans to 
be reprogrammed back into pluripotent cells (60). These 
cells have normal karyotype, express telomerase activity, 
exhibit morphology and markers of hESCs, and maintain 
the developmental potential to differentiate into all cell 
types including neurons, glia, NSCs, and motoneurons 
(23,98,112). Thus, the use of iPSC technology could be 
an alternative therapeutic approach to nonautologous 
transplantation of SC-based therapy for SCI. Derived 
from the patient’s own somatic cells without the usage 
of early embryos, iPSCs represent an ethically accept-
able cell source as opposed to hESCs. In addition, use 
of autologous iPSCs may mitigate the need for immune 
suppression, although this requires careful study. Despite 
their promise, iPSCs are still not approved for clinical tri-
als due to concerns surrounding cell senescence and long-
term tumorigenicity (72). This is due to the FDA and 
European EMA requiring iPSCs to be produced without 
the use of integrating vectors. To date, iPSCs have not 
been put through the extensive preclinical safety required 
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by regulatory agencies, and some data indicate there may 
be an increased tumor risk (72,111). Most iPSCs have 
been generated with integrating vectors, which may not 
be silenced efficiently or could disrupt endogenous genes 
(111). Nevertheless, the field of iPSCs is moving forward 
at an amazing rate, and preclinical efficacy in a rodent 
model of SCI has been established (109). New iPSC gen-
eration methods do not require the use of oncogenes or 
integrating vectors to generate iPSCs. In combination 
with a new technology termed “directed differentiation,” 
many of the reprogramming issues are being solved and 
will alleviate safety concerns (109). It is also important 
to note that the scrutiny placed on the safety of iPSC-
derived transplants must also be leveled on all other com-
peting technologies that require expansion in vitro. For 
example, all individual ESC lines, as well as postnatal 
and adult NSC lines, must go through rigorous in vivo 
testing for tumorigenicity. These guidelines are continu-
ously being altered and leave no short path to clinic. All 
clinical trials approved by regulatory agencies must be 
from cells derived from a mother line or stock of SCs that 
has gone through extensive and expensive safety testing. 
This is in part the reason many companies have vetted 
and remained steadfast toward a particular line of SCs for 
therapeutic trial. It is a financial and time-consuming hur-
dle to generate or even modify a protocol for the deriva-
tion of a therapeutic cell line that limits movement of SCs 
to clinic. In this regard, the use of patient specific iPSCs 
is at a significant disadvantage. Nevertheless, research is 
accelerating toward the development of optimized growth 
and differentiation protocols and reliable safety assays to 
bring the therapeutic potential of iPSCs to life.
Timing and Targets for Stem Cell Therapy
Current and planned SC-based clinical trials in SCI are 
targeting the acutely injured. This is necessitated by the 
relative lack of evidence for therapeutic value of SCs in 
chronic rodent injuries. The acutely injured patient is not 
the ideal population to evaluate recovery of function since 
it is impossible to discern how much natural recovery will 
ensue. Combined with the huge variability in the types 
and levels with which humans exhibit spinal trauma, 
patient selection, and evaluation is a challenge and one 
that needs to be carefully considered. The basis for the 
return of function in rodents is theorized to be remyelina-
tion of spared axons (97). However, the initial patients are 
likely to have little or no spared axons, making remyeli-
nation unlikely to have efficacious results. Nevertheless, 
these trials are very important as they will establish safety 
and lead the way for future work if safety is confirmed. In 
addition, there is a plethora of data indicating that place-
ment of stem or progenitor cells within an acute period 
(0–14 days after injury) have beneficial results (93). This 
remarkable body of literature argues strongly for an acute 
clinical trial despite the challenges of patient selection 
and inherent variability in recovery, which will decrease 
the power of analysis. It may also be a difficult debate 
to decide which cells should be modeled first. Data exist 
for BM, ESCs, hematopoietic cells, adult NSCs, fetal pre-
cursor cells, and postnatal progenitors having benefit in 
the acute setting. With this wide of a cell repertoire but 
a dearth of mechanistic understanding, it is tempting to 
posit that most immature or stem-like cells provide ben-
efit in the acute setting by a general trophic mechanism. 
Until further challenged, we might consider that cell type 
is less important than the factors they produce or the indi-
rect effects they promulgate. Indeed, future work might 
mitigate the need for cells at all and allow clinicians to 
administer SC factors in lieu of transplantation.
In contrast to the widely published evidence for par-
tial repair by transplanting SCs in the acute setting, the 
chronic injury has been less tractable. However, there 
is renewed hope for the chronically injured popula-
tion with limited but rigorous new data showing rodent 
regeneration in the subchronic time period (4–6 weeks 
following injury) (93). Nevertheless, the targets for the 
chronically injured are only slightly better defined than 
for the acute lesion. The most common stated goal of 
chronic transplantation is remyelination of spared axons, 
but the dogmatic assumption of chronic demyelination 
has been recently challenged and needs to be rigorously 
studied in both animal models and patients (61). Similar 
to the findings in peripheral nerve, it appears that demy-
elinated, spared axons may only persist for a short time 
after injury. Combined with evidence of rare or limited 
chronic demyelination in human samples, we must recon-
sider targets and mechanisms in order to accelerate prog-
ress (54). It may also be prudent to adjust future clinical 
trials by enrolling a defined population where physiologi-
cal evidence of chronic demyelination of spared axons is 
unequivocal (9). It is likely that we will have to accept 
that mechanisms of trauma, vascular and inflammatory 
insults, and finally recovery could be more complex, 
subtle, and multimodal. The research community must 
dig deeper into the new studies also showing extensive 
spontaneous remyelination and functional return in the 
chronically injured and be open to novel regenerative 
mechanisms. For example, it may be that the accumulation 
of scar or inhibitory factors in the chronic injury requires 
digestion or blockade in order to unmask myelination 
targets (85,93) or make neuritis responsive to plasticity 
signals. The formation of relay neurons, nonmyelinating 
glia, or supportive astrocytes may be the key to SC-based 
mechanisms that deliver regenerative function. None of 
these mechanisms are exclusive nor have they likely been 
optimized by existing SC transplantation approaches.
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In the past few years, considerable progress has been 
done combining SC-based treatment, bioengineered tis-
sue scaffolds, and peripheral nerve grafts designed to 
provide mechanical support for axonal regrowth and to 
serve as a local delivery system for growth factors or as 
an SC carrier (15,110). A variety of biomaterials, both 
synthetic (polylactic acid, polyglycolic acid) and natural 
(hyaluronic acid, alginate, collagen, agarose, chitosan, 
matrigel, and methylcellulose hydrogel), have been mod-
ified to fabricate tissue scaffolds (99). Some success for 
the formation of neural tissue has been achieved using 
synthetic hydrogels in combination with NSCs, (79,103), 
while transplantation of OECs on hydrogel scaffolds 
resulted with regeneration of dorsal root axons and led 
to increased axonal growth across transected rat spinal 
cords (28). The enhanced regeneration of neurons and 
functional recovery of rats with SCI was seen after use 
of scaffolds that released brain-derived neurotrophic fac-
tor (BDNF) and after transplantation of BDNF-producing 
fibroblasts delivered within alginate matrices (44,107). 
In humans, axonal regeneration beyond the lesion site 
has been noticed in patients who received agarose scaf-
folds seeded with autologous bone marrow stromal cells 
expressing trophic factor neurotrophin-3 (34).
Finally, it is important, with respect to identifying 
therapeutic targets, that we consider the models upon 
which clinical trials are being based. In this regard, stud-
ies looking at the counterindications of cell transplanta-
tion, aside from the obvious caveat of tumor formation, 
are just becoming widespread. For example, most studies 
have not adequately addressed the potential emergence 
of pain syndromes despite literature indicating this is 
possible (20). Any therapy where the goal is to increase 
plasticity may result in unwanted pain fiber growth, 
directly or indirectly. Another modeling concern is that 
existing rodent models typically focus on the recovery 
of locomotion. While rodents are quadrupeds, humans 
utilize inherently more complex bipedal locomotion. 
Locomotion in a quadruped can be facilitated by limited 
regeneration (less than 3% of a tract), whereas human 
control of locomotion may require significantly more 
(104). It will be important to not exceed the public’s 
expectations by assuming that limited repair of quadru-
pedal locomotion will equate to the recovery of walking 
in humans. Many laboratories have added forelimb func-
tional testing, which may be a step in the direction of clin-
ical relevance. This is due to the fact that the wiring and 
utilization of the rodent forepaw is likely more similar 
to humans than locomotion. The majority of human SC 
transplants have been modeled in immune-compromised 
rodents (18). While these results allow us to test the cel-
lular basis of recovery without xenograft rejection, they 
leave in question how the intact immune system will 
augment or interfere with SC function clinically. Finally, 
if current and near-future clinical trials fail to show any 
efficacy it may signal that the complexity of the human 
nervous system and immune system has been underes-
timated. This may argue that larger model species, such 
as dogs or monkeys, are important intermediaries before 
the next leap to humans (9,45).
Autologous or Allogenic Stem Cell Therapy  
for Spinal Cord Injury?
Among all human stem cells, MSCs are the best candi-
dates for allogenic stem cell therapy. The culture-expanded 
human MSCs express only major histocompatibility com-
plex (MHC) class I molecules, do not express MHC class 
II and costimulator molecules (62), cannot be antigen-
presenting cells, and are invisible to the host’s immune 
system after transplantation (55,108). Both autologous and 
allogenic MSC transplantation showed therapeutic effect 
in the experimental model of SCI (46). From a therapeutic 
point of view, autologous MSCs exhibited more benefi-
cial therapeutic potential than allogenic MSCs, but both 
autologous and allogenic MSCs managed to rehabilitate 
locomotor and nociceptive function in dogs with SCI (46). 
In addition, 5 weeks after injury, the size of the spinal cord 
lesions was approximately the same among autologous and 
allogeneic MSC-treated groups but significantly reduced 
when compared with untreated animals.
Clinical studies using allogenic stem cells are rare 
because of the concerns about safety. The human leukocyte 
antigen (HLA) compatibility must be first considered in all 
allogenic clinical trials because the transplantation of HLA-
mismatched SCs is unsafe. Kang and colleagues reported 
a case study of allogenic HLA-matched human umbilical 
cord blood-derived stem cell (hUCBSC) transplantation 
into the injured spinal cord site of a 37-year-old female 
patient with SCI (47). The hUCBSCs managed to improve 
sensory perception and movement in the patient’s hips 
and thighs within 41 days of cell transplantation. Multiple 
radiological analyses suggested that hUCBSC therapy led 
to a regeneration of the spinal cord at the injured site and at 
some of the cauda equina below it (47). Despite promising 
results obtained from this study, it is noteworthy to men-
tion that hUCBSCs are known to be more immune naive 
than any other adult cells (81). Therefore, safety issues 
such as immune reaction in HLA-mismatched allogeneic 
transplantation must be considered in all future allogeneic 
clinical trials.
CONCLUSIONS
The main goal of SC-based therapy for SCI is the regen-
eration and replacement of neurons and glial cells that 
undergo cell death soon after injury. Stem cells represent 
the newest and the most successful therapeutic approach 
for SCI, enabling improved and efficient sensory and 
motor functions in animal models. Stem cells are able to 
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promote remyelination via oligodendroglial cell replace-
ment; produce trophic factors enhancing neurite outgrowth, 
axonal elongation, and fiber density; and activate resident 
or transplanted progenitor cells across the lesion cavity. 
Despite this, we have yet to validate specific mechanisms 
for SC transplantation. Published data supporting acute 
transplantation outweigh chronic intervention 100 to 1, but 
this is fortunately changing. Many investigators push hard 
to establish cell type-specific mechanisms of recovery, 
while others have begun to ask if trophic factors or immune 
modulation is in itself the mechanistic basis of acute SC 
therapy. Numerous studies suggest that SCs are able to 
enhance recovery following SCI, but no single SC type, 
when transplanted, seems sufficient to support a robust 
regenerative response that will lead to complete recovery 
of SCI. Successful SC-based therapy for SCI requires bet-
ter understanding of SC differentiation pathways and SC 
survival upon transplantation. Protocols for differentia-
tion of hESCs, MSCs, OECs, NSCs, and iPSCs into pure 
population of functional neural cells need improvement. 
Further reproducible studies using animal especially pri-
mate models should be done in order to investigate the 
precise mechanisms of reconstructing pathways and syn-
apses, integration, survival, and action of transplanted 
SCs in injured spinal cord. Therefore, the first long-term 
results of the trials focused on impact of stem cell-based 
therapies for SCI are eagerly awaited. Until then, the ideal 
source of SCs for efficient and safe cell-based therapy for 
SCI remains a challenging issue that requires more inves-
tigation and continuous cooperation between clinicians, 
researchers, and patients.
KEY MESSAGES
The main goal of SC-based therapy for SCI is regen-•	
eration and replacement of neurons and glial cells 
that undergo cell death soon after injury.
Transplantation of hESC-derived OPCs and MPs •	
efficiently recovered locomotor function both in 
contusion and transection animal models of SCI.
The most widely applied SC-based therapy for •	
SCI treatment in humans is transplantation of bone 
marrow-derived MSCs that are thought to act as a 
neuroprotectors by secreting various angiogenic and 
neurotrophic factors. However, the proof of func-
tional neurons derived from transplanted MSCs has 
not been provided yet.
Several preclinical studies showed that transplan-•	
tation of adult spinal cord-derived NSCs promote 
early functional recovery after SCI through differ-
entiation into oligodendrocytes.
Reprogramming of somatic cells back to the pluri-•	
potency stage by transducing a few key transcrip-
tion factors results in the creation of iPSCs and 
represents a novel patient specific therapeutic 
approach for SCI treatment.
iPSCs are still not allowed in initial clinical trials •	
due to concerns about their tumorigenicity.
The ideal source of SCs for efficient and safe cell-•	
based therapy for SCI remains a challenging issue 
that requires more investigation and continuous 
cooperation between clinicians, researchers, and 
patients that should result with new SC-based strat-
egies for the safe and successful treatment of SCI.
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